

Virginia Provider Communications

Updates to AIM Advanced Oncologic Imaging Clinical Appropriateness Guideline

Published: Aug 1, 2019

Effective for dates of service on and after **July 14, 2019**, the following updates will apply to the AIM Advanced Oncologic Imaging Clinical Appropriateness Guideline.

Prostate Cancer

Added criteria for the appropriate use of PET-CT with the radiotracers Axumin and 11-Choline, establishing the position of this test in the care continuum for prostate cancer primarily related to biochemical recurrence

Neuroendocrine Tumors

Added criteria for the appropriate use of PET-CT with the radiotracer DOTA-TATE establishing the position of this test in the care continuum for neuroendocrine tumors

As a reminder, ordering and servicing providers may submit prior authorization requests to AIM in one of several ways:

- Access AIM's **ProviderPortal**_{SM} directly at providerportal.com. Online access is available 24/7 to process orders in real-time, and is the fastest and most convenient way to request authorization.
- Access AIM via the Availity Web Portal at availity.com.
- Call the AIM Contact Center toll-free number: 866-789-0397, Monday - Friday, 8 a.m. to 5 p.m. ET

For questions related to guidelines, please contact AIM via email at aim.guidelines@aimspecialtyhealth.com. Additionally, you may access and download a copy of the [current guidelines](#).

<https://providernews.anthem.com/virginia/article/updates-to-aim-advanced-oncologic-imaging-clinical-appropriateness-guideline-4>

Virginia Provider Communications

Featured In:
August 2019 Anthem Provider News - Virginia